Rhabdomyosarcoma - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Rhabdomyosarcoma - Pipeline Review, H2 2018’, provides an overview of the Rhabdomyosarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rhabdomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rhabdomyosarcoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rhabdomyosarcoma

- The report reviews pipeline therapeutics for Rhabdomyosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Rhabdomyosarcoma therapeutics and enlists all their major and minor projects

- The report assesses Rhabdomyosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Rhabdomyosarcoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Rhabdomyosarcoma

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Rhabdomyosarcoma pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amgen Inc

Bayer AG

Bellicum Pharmaceuticals Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Celgene Corp

Cellectar Biosciences Inc

Cellestia Biotech AG

Eisai Co Ltd

Epizyme ...

Amgen Inc

Bayer AG

Bellicum Pharmaceuticals Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Celgene Corp

Cellectar Biosciences Inc

Cellestia Biotech AG

Eisai Co Ltd

Epizyme Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Iproteos SL

Ipsen SA

MacroGenics Inc

NantKwest Inc

Novartis AG

Noxxon Pharma AG

Pfizer Inc

Taiho Pharmaceutical Co Ltd

Taiwan Liposome Company Ltd

Tarveda Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Rhabdomyosarcoma - Overview 6

Rhabdomyosarcoma - Therapeutics Development 7

Rhabdomyosarcoma - Therapeutics Assessment 15

Rhabdomyosarcoma - Companies Involved in Therapeutics ...

Table of Contents

Table of Contents 2

Introduction 5

Rhabdomyosarcoma - Overview 6

Rhabdomyosarcoma - Therapeutics Development 7

Rhabdomyosarcoma - Therapeutics Assessment 15

Rhabdomyosarcoma - Companies Involved in Therapeutics Development 25

Rhabdomyosarcoma - Drug Profiles 36

Rhabdomyosarcoma - Dormant Projects 297

Rhabdomyosarcoma - Discontinued Products 298

Rhabdomyosarcoma - Product Development Milestones 299

Appendix 302

List of Tables

List of Tables

Number of Products under Development for Rhabdomyosarcoma, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Tables

Number of Products under Development for Rhabdomyosarcoma, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Rhabdomyosarcoma - Pipeline by Amgen Inc, H2 2018

Rhabdomyosarcoma - Pipeline by Bayer AG, H2 2018

Rhabdomyosarcoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2018

Rhabdomyosarcoma - Pipeline by Boehringer Ingelheim GmbH, H2 2018

Rhabdomyosarcoma - Pipeline by Bristol-Myers Squibb Co, H2 2018

Rhabdomyosarcoma - Pipeline by Celgene Corp, H2 2018

Rhabdomyosarcoma - Pipeline by Cellectar Biosciences Inc, H2 2018

Rhabdomyosarcoma - Pipeline by Cellestia Biotech AG, H2 2018

Rhabdomyosarcoma - Pipeline by Eisai Co Ltd, H2 2018

Rhabdomyosarcoma - Pipeline by Epizyme Inc, H2 2018

Rhabdomyosarcoma - Pipeline by Exelixis Inc, H2 2018

Rhabdomyosarcoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Rhabdomyosarcoma - Pipeline by Iproteos SL, H2 2018

Rhabdomyosarcoma - Pipeline by Ipsen SA, H2 2018

Rhabdomyosarcoma - Pipeline by MacroGenics Inc, H2 2018

Rhabdomyosarcoma - Pipeline by NantKwest Inc, H2 2018

Rhabdomyosarcoma - Pipeline by Novartis AG, H2 2018

Rhabdomyosarcoma - Pipeline by Noxxon Pharma AG, H2 2018

Rhabdomyosarcoma - Pipeline by Pfizer Inc, H2 2018

Rhabdomyosarcoma - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2018

Rhabdomyosarcoma - Pipeline by Taiwan Liposome Company Ltd, H2 2018

Rhabdomyosarcoma - Pipeline by Tarveda Therapeutics Inc, H2 2018

Rhabdomyosarcoma - Dormant Projects, H2 2018

Rhabdomyosarcoma - Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Rhabdomyosarcoma, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Figures

Number of Products under Development for Rhabdomyosarcoma, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports